{
    "nctId": "NCT00709020",
    "briefTitle": "White Button Mushroom Extract in Preventing the Recurrence of Breast Cancer in Postmenopausal Breast Cancer Survivors",
    "officialTitle": "A Translational Breast Cancer Prevention Trial of Mushroom Powder in Postmenopausal Breast Cancer Survivors",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Cancer Survivor",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 16,
    "primaryOutcomeMeasure": "Efficacy of white button mushroom extract (WBM) in reducing serum estradiol (E2)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Meets 1 of the following criteria:\n\n  * Prior diagnosis of infiltrating carcinoma of the breast \u2265 5 years prior to study entry\n  * Prior diagnosis of ductal carcinoma in situ\n* No evidence of disease\n* Completed all cancer therapy, with the exception of reconstructive surgery, at least 6 months prior to study entry\n* Meets one of the following criteria:\n\n  * Normal mammogram within 1 year of study entry\n  * Underwent bilateral mastectomy and has been in remission for 5 years, as documented by an oncologist\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-1\n* WBC \u2265 3,500/mm\u00b3\n* ANC \u2265 1,500/mm\u00b3\n* Platelet count \u2265 100,000/mm\u00b3\n* Hemoglobin \u2265 9.0 g/dL\n* Postmenopausal, defined as any of the following:\n\n  * Continuous absence of menstruation for 12+ months\n  * Status post bilateral oophorectomy\n  * Status post hysterectomy with follicle-stimulating hormone in menopausal range\n* Creatinine \u2264 1.5 times upper limit of normal (ULN) or less\n* Total bilirubin \u2264 1.5 times ULN\n* AST and ALT \\< 2 times ULN\n* No allergy to mushrooms\n* No personal history of any invasive cancer, other than breast cancer, or squamous cell or basal cell skin cancer\n* No osteoporosis, defined as a bone-mineral density T-score of \\< -2.5 on dual-energy x-ray absorptiometry scan\n* No major systemic infections or other major medical illnesses of the cardiovascular, respiratory, or digestive system\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* More than 3 months since prior and no concurrent hormone-modifying medications, including any of the following:\n\n  * Oral contraceptives\n  * Hormone replacement\n  * Selective estrogen receptor modifiers\n  * Other aromatase inhibitors\n  * Gonadotropic-releasing hormone modifiers\n* At least 1 month since prior and no other concurrent mushroom extracts or DHEA as a dietary supplement\n* No concurrent therapy, except continued medications for unrelated illness that are not excluded, and necessary medications for unrelated acute illnesses that may occur during the study (e.g., cold, flu, or infection)\n* No more than 3 concurrent servings per week of the following foods:\n\n  * Flaxseeds and flaxseed meal\n  * High-energy bars or diet bars containing soy or soy protein\n  * Liquid-nutrition drinks containing soy or soy protein (e.g., Odwalla Future Shake or Ensure Plus)\n  * Miso soup\n  * Natto\n  * Packaged mixed dishes with soy or tofu (e.g., lasagna, burritos, or stir-fry)\n  * Cooked soybeans or edamame (i.e., green soybeans)\n  * Roasted soy nuts\n  * Soymilk, regular or low-fat, plain or flavored\n  * Soy cheese, such as cheddar, mozzarella, cram cheese, or parmesan (includes all foods made with soy cheese)\n  * Soy protein powders (e.g., performance or body-builder powders)\n  * Soy yogurt, all types\n  * Soy sauce, tamari, teriyaki sauce, Szechuan sauce, or hoisin sauce\n  * Soy ice cream, tofutti, or other soy desserts\n  * Tempeh, all types\n  * Tofu, all types, including low-fat, flavored, marinated, and smoked\n  * Tofu or soy breakfast sausage, bacon, or other breakfast meat\n  * Tofu or soy cold cuts, hot dogs, or other deli meat substitutes\n  * Veggie soy or tofu burger, ground meat substitute (texturized vegetable protein), or soy or tofu, chicken, or turkey\n* Concurrent supplemental calcium and/or vitamin D and bisphosphonates allowed provided doses remain constant throughout the run-in and treatment portions of the trial",
    "sex": "FEMALE",
    "minimumAge": "21 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}